TX-ZILLIANT
6.1.2022 13:02:04 CET | Business Wire | Press release
Zilliant , the industry leader in intelligent B2B price optimization, price management and sales guidance software, today introduced the Real-Time Pricing Engine™, a new product that enables business-to-business (B2B) companies to calculate and deliver prices in real-time to any commercial system.
Executing pricing logic and delivering prices in real-time to digital commerce channels is often beyond the capabilities of many companies’ existing pricing engines. The Zilliant Real-Time Pricing Engine™ meets the growing need for a faster, more robust way of handling the pricing demands of complex omnichannel B2B companies. The solution’s high-availability, high-performance REST API with 99.99% guaranteed uptime instantaneously executes complex pricing logic, and performs complex calculations, including external data lookups, to deliver prices to any ERP, CRM, CPQ, eCommerce platform or mobile application.
“We set out to help customers power intelligent commerce in the digital age, and the Real-Time Pricing Engine™ is one of the most effective tools to accomplish that,” said Zilliant President and Chief Executive Officer Greg Peters. “Companies seeking to be more dynamic in their approach to pricing are no longer constrained by the limitations of legacy systems. With real-time pricing, they can execute complex pricing calculations in milliseconds.”
The Rise of B2B Digital Commerce Calls for Real-Time Pricing
Gartner has mentioned pricing as one of the core functional components of a commerce platform. In the report, “Harness the Core Capabilities of a Digital Commerce Platform ,” Gartner states pricing “may need to be real-time if pricing is highly dynamic. Real-time integrations to ERP are fraught with performance risks, so often, caching layers or other forms of ERP protection must be in place. [The] interaction of pricing with promotional engines can be complex and must be approached with caution. Pricing management is an area of growing sophistication and disruption. Third-party point solutions are often required to take advantage of innovations.”1
“36% of B2B buyers say an inability to get the best price online is a significant barrier to doing more business via the digital commerce channel,” stated Gartner Senior Research Director, Mark Lewis in a report.2 “To unblock those potential buyers, it’s essential to employ an AI-driven, real-time and value-based pricing engine, which can consider competition, customer profile, stock availability, etc. to come up with the best price for each buying situation. Not all customers have to see the same prices. This model is employed successfully to optimize the profits of airlines, hotels and car rental companies. In this situation, customers must understand that they are seeing a spot price that can go up or down. Most importantly, they must get the same spot price regardless of channel interaction.”2
Zilliant Real-Time Pricing Engine™ ─ in conjunction with Zilliant Price Manager™ ─ meets the need for a third-party point solution to effectively manage and house pricing logic and reliably calculate and deliver the correct price for a customer in real-time. In practice, each transaction or quote request triggers a complex pricing build or look up to determine the right price, along with its attendant taxes, fees and discounts. Further, the proliferation of scenarios that require on-demand pricing is vast; it’s not uncommon for tens of thousands of pricing requests to flow through a company in various channels daily. Companies can significantly increase the speed, accuracy and consistency of pricing – as well as the pricing negotiation process – by using the Real-Time Pricing Engine™ and Price Manager™ to automate negotiations, counteroffers and approvals based on pre-defined parameters.
Learn more about real-time pricing and the Zilliant Real-Time Pricing Engine™ .
1 Gartner, “Harness the Core Capabilities of a Digital Commerce Platform,” Mike Lowndes, Christina Klock, published September 4, 2019 and refreshed on February 9, 2021.
2 Gartner, “Increase Profits and Delight Buyers by Becoming a Digital-First, Omnichannel B2B Seller,” Mark Lewis, April 1, 2021.
Gartner Disclaimer:
GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Zilliant
Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005137/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom